Summary

Eligibility
for people ages up to 3 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around

Description

Summary

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.

Official Title

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Details

Keywords

Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Syndrome, Cytarabine, Etoposide, Podophyllotoxin, Daunorubicin, Mitoxantrone, Etoposide phosphate, Asparaginase, Mercaptopurine, Thioguanine, recombinant-rywn Asparaginase erwinia chrysanthemi, 2-Aminopurine, Asparaginase Erwinia chrysanthemi, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT02521493
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 280 people participating
Last Updated